Regeneron Pharmaceuticals, Inc.
REGN
$788.00
$10.001.29%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.16% | 5.24% | 4.84% | 6.55% | -5.53% |
| Total Other Revenue | 21.45% | 44.06% | 38.72% | 46.84% | 39.46% |
| Total Revenue | 5.72% | 6.46% | 5.90% | 7.76% | -4.47% |
| Cost of Revenue | 11.10% | 12.39% | -1.11% | 2.44% | -2.29% |
| Gross Profit | 2.22% | 2.74% | 11.45% | 11.66% | -5.84% |
| SG&A Expenses | 13.54% | 15.69% | 19.95% | 24.36% | 26.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 458.54% | 154.12% | 119.52% | 97.66% | 91.73% |
| Total Operating Expenses | 12.18% | 14.21% | 18.95% | 23.75% | 20.61% |
| Operating Income | -7.00% | -8.01% | -15.31% | -15.23% | -32.25% |
| Income Before Tax | 13.55% | -3.94% | -13.18% | -13.57% | -27.51% |
| Income Tax Expenses | -18.27% | -44.27% | -61.06% | -52.79% | -42.25% |
| Earnings from Continuing Operations | 16.62% | 0.53% | -7.77% | -8.87% | -25.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.62% | 0.53% | -7.77% | -8.87% | -25.68% |
| EBIT | -7.00% | -8.01% | -15.31% | -15.23% | -32.25% |
| EBITDA | -5.13% | -6.15% | -12.85% | -12.77% | -29.40% |
| EPS Basic | 15.72% | 0.31% | -7.49% | -8.55% | -25.75% |
| Normalized Basic EPS | -2.56% | -1.91% | -8.58% | -9.37% | -26.85% |
| EPS Diluted | 15.29% | -0.16% | -8.00% | -9.11% | -26.10% |
| Normalized Diluted EPS | -2.96% | -2.38% | -9.13% | -9.95% | -27.18% |
| Average Basic Shares Outstanding | 0.75% | 0.19% | -0.28% | -0.37% | -0.09% |
| Average Diluted Shares Outstanding | 1.14% | 0.66% | 0.31% | 0.26% | 0.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
